Nuffield Department of Population Health, University of Oxford, UK.
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK.
J Gerontol A Biol Sci Med Sci. 2021 Jun 14;76(7):1295-1302. doi: 10.1093/gerona/glab069.
Chronological age is the strongest risk factor for most chronic diseases. Developing a biomarker-based age and understanding its most important contributing biomarkers may shed light on the effects of age on later-life health and inform opportunities for disease prevention.
A subpopulation of 141 254 individuals healthy at baseline were studied, from among 480 019 UK Biobank participants aged 40-70 recruited in 2006-2010, and followed up for 6-12 years via linked death and secondary care records. Principal components of 72 biomarkers measured at baseline were characterized and used to construct sex-specific composite biomarker ages using the Klemera Doubal method, which derived a weighted sum of biomarker principal components based on their linear associations with chronological age. Biomarker importance in the biomarker ages was assessed by the proportion of the variation in the biomarker ages that each explained. The proportions of the overall biomarker and chronological age effects on mortality and age-related hospital admissions explained by the biomarker ages were compared using likelihoods in Cox proportional hazard models.
Reduced lung function, kidney function, reaction time, insulin-like growth factor 1, hand grip strength, and higher blood pressure were key contributors to the derived biomarker age in both men and women. The biomarker ages accounted for >65% and >84% of the apparent effect of age on mortality and hospital admissions for the healthy and whole populations, respectively, and significantly improved prediction of mortality (p < .001) and hospital admissions (p < 1 × 10-10) over chronological age alone.
This study suggests that a broader, multisystem approach to research and prevention of diseases of aging warrants consideration.
年龄是大多数慢性疾病的最强风险因素。开发基于生物标志物的年龄并了解其最重要的贡献生物标志物,可以揭示年龄对晚年健康的影响,并为疾病预防提供机会。
在 2006-2010 年招募的 480019 名年龄在 40-70 岁的 UK Biobank 参与者中,研究了 141254 名基线健康的亚群,并通过链接的死亡和二级护理记录进行了 6-12 年的随访。在基线测量的 72 种生物标志物的主成分进行了特征描述,并使用 Klemera Doubal 方法使用基于与年龄呈线性关联的生物标志物主成分的加权和构建了性别特异性综合生物标志物年龄。通过每个生物标志物在生物标志物年龄中的解释比例来评估生物标志物在生物标志物年龄中的重要性。通过 Cox 比例风险模型中的似然比比较生物标志物年龄和生物标志物年龄对死亡率和与年龄相关的住院的整体和年龄效应在死亡率和与年龄相关的住院中的解释比例。
在男性和女性中,肺活量降低、肾功能下降、反应时间、胰岛素样生长因子 1、手握力和更高的血压是导致衍生生物标志物年龄的关键因素。生物标志物年龄分别解释了健康人群和整个人群中年龄对死亡率和住院的明显影响的>65%和>84%,并且显著改善了死亡率(p <.001)和死亡率的预测(p < 1×10-10)单独基于年龄的住院。
本研究表明,需要考虑更广泛、多系统的衰老疾病研究和预防方法。